Provided by Tiger Fintech (Singapore) Pte. Ltd.

Seres Therapeutics

0.6898
+0.05148.05%
Post-market: 0.6600-0.0298-4.32%19:11 EDT
Volume:812.35K
Turnover:548.49K
Market Cap:117.78M
PE:-3.93
High:0.6900
Open:0.6500
Low:0.6400
Close:0.6384
Loading ...

Seres Therapeutics Receives Feedback From FDA on Ser-155 Allogeneic Hematopoietic Stem Cell Transplant (Allo-Hsct) Development Approach

THOMSON REUTERS
·
03 Mar

Seres Therapeutics Inc - Expects FDA Response on Ser-155 Study Protocol in Weeks

THOMSON REUTERS
·
03 Mar

Seres Therapeutics Inc - Ser-155 Receives Breakthrough Therapy and Fast Track Designations

THOMSON REUTERS
·
03 Mar

Seres Therapeutics Receives Feedback From FDA on SER-155 Allogeneic Hematopoietic Stem Cell Transplant (allo-HSCT) Development Approach

GlobeNewswire
·
03 Mar

Seres Therapeutics Inc expected to post a loss of 20 cents a share - Earnings Preview

Reuters
·
28 Feb

Sector Update: Health Care Stocks Flat to Lower Premarket Thursday

MT Newswires Live
·
16 Jan

Seres Therapeutics Receives First of 2 Installments Related to VOWST Sale

MT Newswires Live
·
16 Jan

Seres Therapeutics Announces Receipt of Expected $50 Million Installment Payment Related to Vowst Sale

THOMSON REUTERS
·
16 Jan

Press Release: Seres Therapeutics Announces Receipt of Expected $50 Million Installment Payment Related to VOWST Sale

Dow Jones
·
16 Jan

Seres Therapeutics Reports 'Positive Impact' in SER-155 Early Trial; Cash Runway Extended

MT Newswires Live
·
10 Jan

Seres announces new translational biomarker results from SER-155 Phase 1b study

TIPRANKS
·
09 Jan

Seres Therapeutics Inc - Extends Cash Runway Into Q1 2026

THOMSON REUTERS
·
09 Jan

Seres Therapeutics Inc - Ser-155 Shows 77% Relative Risk Reduction in Bloodstream Infections

THOMSON REUTERS
·
09 Jan

Seres Therapeutics Announces New Translational Biomarker Results From Ser-155 Phase 1B Clinical Study and Provides Corporate Updates

THOMSON REUTERS
·
09 Jan

Seres Therapeutics Inc - Ser-155 Shows Significant Decrease in Fecal Albumin and Systemic Inflammation

THOMSON REUTERS
·
09 Jan

Seres Therapeutics Announces New Translational Biomarker Results from SER-155 Phase 1b Clinical Study and Provides Corporate Updates

GlobeNewswire
·
09 Jan